Skip to main content

Table 4 Treatment-Related Toxicities

From: The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study

Adverse Event Grade1 n(%) Grade2 n(%) Grade3 n(%) Grade4 n(%) Total n(%)
Monotherapy group(n = 12)
 Secondary hypertension 1 (8.3) 2 (16.7) 1 (8.3) 1 (8.3) 5 (41.7)
 Hand-foot syndrome 1 (8.3) 1 (8.3) 1 (8.3) 0 3 (25.0)
 Proteinuria 2 (16.7) 0 0 0 2 (16.7)
 Fatigue 1 (8.3) 2 (16.7) 0 0 3 (25.0)
 Diarrhea 1 (8.3) 0 0 0 1 (8.3)
Combination group(n = 16)
 Secondary hypertension 2 (12.5) 1 (6.3) 0 0 3 (18.8)
 Hand-foot syndrome 1 (6.3) 2 (12.5) 0 0 3 (18.8)
 Proteinuria 2 (12.5) 0 0 0 2 (12.5)
 Nausea 2 (12.5) 2 (12.5) 0 0 4 (25.0)
 Neutropenia 5 (31.3) 1 (6.3) 1 (6.3) 0 7 (43.8)